SCHEMBL1863728 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	SPHK1	Q9NYA1	1/20	0.46

▸	HSD11B2	P80365	1/20	0.40

▸	BRD4	O60885	2/20	0.38

▸	HCRTR2	O43614	1/20	0.36

▸	CHRM2	P08172	1/20	0.33

▸	CHRM1	P11229	1/20	0.33

▸	CHRM3	P20309	1/20	0.33

▸	ALDH1A1	P00352	1/20	0.33

▸	NPSR1	Q6W5P4	1/20	0.33

▸	KDM4E	B2RXH2	1/20	0.32

▸	PKM	P14618	1/20	0.32

▸	DDB1	Q16531	1/20	0.32

▸	CRBN	Q96SW2	1/20	0.32

▸	USP2	O75604	1/20	0.32

▸	SMN1; SMN2	Q16637	1/20	0.32

▸	NR1H2	P55055	1/20	0.31

▸	EPHX2	P34913	1/20	0.31

▸	TSHR	P16473	1/20	0.31

▸	HSD17B10	Q99714	1/20	0.31

▸	NAMPT	P43490	1/20	0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL14489664	1.00	SPHK1 (0.46)	SPHK1HSD11B2BRD4HCRTR2CHRM2
SCHEMBL1863729	1.00	SPHK1 (0.46)	SPHK1HSD11B2BRD4HCRTR2CHRM2
SCHEMBL28067987	0.87	SPHK1 (0.49)	SPHK1HSD11B2BRD4HCRTR2CHRM2
SCHEMBL16325799	0.87	SPHK1 (0.49)	SPHK1HSD11B2BRD4HCRTR2CHRM2
SCHEMBL13613722	0.87	SPHK1 (0.49)	SPHK1HSD11B2BRD4HCRTR2CHRM2
SCHEMBL7494707	0.87	SPHK1 (0.43)	SPHK1HSD11B2BRD4HCRTR2CHRM2
SCHEMBL2326706	0.87	SPHK1 (0.45)	SPHK1HSD11B2BRD4HCRTR2CHRM2
SCHEMBL6918603	0.87	SPHK1 (0.45)	SPHK1HSD11B2BRD4HCRTR2CHRM2
SCHEMBL2326704	0.87	SPHK1 (0.45)	SPHK1HSD11B2BRD4HCRTR2CHRM2
SCHEMBL4594516	0.86	SPHK1 (0.48)	SPHK1HSD11B2BRD4HCRTR2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-3037424-B1	NOVEL QUINOLINE-SUBSTITUTED COMPOUND	TAIHO PHARMACEUTICAL CO LTD (JP)	2017-11-08	—	—	EP	disclosed
US-9758526-B2	Quinoline-substituted compound	TAIHO PHARMACEUTICAL CO., LTD. (JP)	2017-09-12	—	—	US	disclosed
US-9758526-B2	Quinoline-substituted compound	TAIHO PHARMACEUTICAL CO., LTD. (JP)	2017-09-12	—	—	US	disclosed
US-9650386-B2	Quinoline-substituted compound	Taiho Pharmaceutical Co., Inc. (JP)	2017-05-16	—	—	US	disclosed
US-9650386-B2	Quinoline-substituted compound	Taiho Pharmaceutical Co., Inc. (JP)	2017-05-16	—	—	US	disclosed
US-20170101414-A1	NOVEL QUINOLINE-SUBSTITUTED COMPOUND	TAIHO PHARMACEUTICAL CO., LTD. (JP)	2017-04-13	—	—	US	disclosed
US-20170101414-A1	NOVEL QUINOLINE-SUBSTITUTED COMPOUND	TAIHO PHARMACEUTICAL CO., LTD. (JP)	2017-04-13	—	—	US	disclosed
US-20160194332-A1	NOVEL QUINOLINE -SUBSTITUTED COMPOUND	TAIHO PHARMACEUTICAL CO., LTD. (JP)	2016-07-07	—	—	US	disclosed
US-20160194332-A1	NOVEL QUINOLINE -SUBSTITUTED COMPOUND	TAIHO PHARMACEUTICAL CO., LTD. (JP)	2016-07-07	—	—	US	disclosed
EP-3037424-A1	NOVEL QUINOLINE-SUBSTITUTED COMPOUND	Taiho Pharmaceutical Co., Ltd. (JP)	2016-06-29	—	—	EP	disclosed
US-8455521-B2	Diaminoalkane aspartic protease inhibitors	VITAE PHARMACEUTICALS, INC. (US)	2013-06-04	—	—	US	disclosed
EP-1966139-B1	ASPARTIC PROTEASE INHIBITORS	VITAE PHARMACEUTICALS INC (US)	2011-12-21	—	—	EP	disclosed
US-20110105506-A1	Diaminoalkane aspartic protease inhibitors	VITAE PHARMACEUTICALS, INC.	2011-05-05	—	—	US	disclosed
US-7754737-B2	Diaminoalkane aspartic protease inhibitors	VITAE PHARMACEUTICALS, INC. (US)	2010-07-13	—	—	US	disclosed
US-20100048636-A1	Aspartic Protease Inhibitors	VITAE PHARMACEUTICALS, INC.	2010-02-25	—	—	US	disclosed
US-20090018103-A1	Diaminoalkane Aspartic Protease Inhibitors	VITAE PHARMACEUTICAL, INC (US)	2009-01-15	—	—	US	disclosed
EP-1966139-A1	ASPARTIC PROTEASE INHIBITORS	Vitae Pharmaceuticals, Inc. (US)	2008-09-10	—	—	EP	disclosed
EP-1807078-A1	DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS	Vitae Pharmaceuticals, Inc. (US)	2007-07-18	—	—	EP	disclosed
WO-2007070201-A1	ASPARTIC PROTEASE INHIBITORS	VITAE PHARMACEUTICALS, INC. (US)	2007-06-21	—	—	WO	disclosed
WO-2006042150-A1	DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS	VITAE PHARMACEUTICALS, INC. (US)	2006-04-20	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20100048636-A1	Aspartic Protease Inhibitors	DNPEP, PEPD, SERPINB1	SPHK1 1780/4885HSD11B2 1404/4885BRD4 2123/4885
US-20110105506-A1	Diaminoalkane aspartic protease inhibitors	DNPEP, PEPD, ACE	SPHK1 854/4885HSD11B2 2607/4885BRD4 2787/4885
US-20090018103-A1	Diaminoalkane Aspartic Protease Inhibitors	DNPEP, PEPD, ACE	SPHK1 854/4885HSD11B2 2607/4885BRD4 2787/4885
US-20170101414-A1	NOVEL QUINOLINE-SUBSTITUTED COMPOUND	EGFR, ERBB2, ERBB4	SPHK1 3784/4885HSD11B2 3873/4885BRD4 132/4885
US-20160194332-A1	NOVEL QUINOLINE -SUBSTITUTED COMPOUND	EGFR, ERBB2, ERBB4	SPHK1 3784/4885HSD11B2 3873/4885BRD4 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.